

HHCP-I-3D Human Hepatocytes Cryopreserved Plateable for Induction assays and for 3D culture
Cell Specification – Certificate of Analysis (CoA)

Lot HH250124

Batch Release: May 30, 2025

Donor data

Species: Human

Gender: male

Age: 74 years

Diagnosis: Rectum carcinoma with liver metastasis

Medical History: Hypertension

Non-smoker

Therapy: Hemihepatectomy right

Medication: Ramipril, Allopurinol

Serology: HAV, HBV, HCV, HIV 1/2: negative

Cryopreservation and Thawing

Cryopreservation:

Date: Jan 24, 2025

Amount per vial: 7.98×10^6 cells

Thawing: n=1


Post-thaw viability: 91.4 %

Post-thaw yield per vial: 4.7×10^6 cells


Recovery: 59 %

2D culture

Phase contrast on day 1 after thawing
(24well plate)



Phase contrast on day 3 after thawing
(24well plate)





Recommended seeding density on Corning or Greiner collagen-coated plates:

24well plate – 300,000 cells/well // 96well plate – 80,000 cells/well.

Culture in Human Hepatocyte Maintenance Medium (HHMM).

CYP P450 activity in 2D culture after thawing: Ethoxyresorufin-O-deethylation: Induction with 25 µM β-Naphthoflavone	pmol/(mg × min) 24well: 11.7 ± 0.6 96well: 22.8 ± 2.7	X-fold induction 3.5 4.9
--	---	--------------------------------

3D culture	
Cells seeded in 96well ULA round bottom plates (FaCellitate), 2,500 cells/well	
day 4	day 8
	

Suspension culture

Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10⁶ cells in 0.5 ml HPM-Cryo):

Time (h)	0	1	2	3	4	5
Viability (%)	91.4	77.6	79.9	86.1	83.1	85.5

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT’s manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Store at -150 °C or in the vapour phase of LN₂

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: A. Ullrich	Verified by: K. Damrau
-----------------------	------------------------